Welcome to our dedicated page for Lexaria Bioscience Warrant news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience Warrant stock.
Lexaria Bioscience Corp. (NASDAQ:LEXXW) is a global innovator in drug delivery platforms known for its patented drug delivery technology, DehydraTECH. DehydraTECH enhances the absorption of active pharmaceutical ingredients, such as cannabinoids and nicotine, by promoting more effective oral delivery. The technology has shown to significantly increase bio-absorption, reduce onset times, and mask unwanted tastes. Lexaria operates in four main segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate. With a robust intellectual property portfolio and ongoing research, Lexaria aims to revolutionize drug delivery methods and improve outcomes.
Lexaria Bioscience Corp. (LEXX, LEXXW) released promising initial results from its human clinical study HYPER-H21-2, showing a significant 23% decrease in blood pressure (BP) with DehydraTECH-CBD compared to placebo. Over 24 hours, volunteers experienced an average 20 mmHg reduction in BP and a notable 7.0% decrease in systolic pressure (p < 0.001). The study indicates DehydraTECH-CBD's potential as a tolerable treatment for hypertension, with no serious side effects reported. Further data analyses are ongoing, and Lexaria plans to conduct additional studies to explore long-term effects.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) released partial results from the human clinical study HYPER-H21-1, showing that DehydraTECH-CBD significantly reduces blood pressure in hypertensive patients. The study, involving 24 volunteers aged 45-65, reported up to a 13 mmHg reduction in systolic blood pressure within 50 minutes of administration. No serious side effects were observed, unlike the control group using generic CBD. Lexaria plans further analyses and continued research to enhance efficacy through repeat dosing.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announces significant growth as its DehydraTECHTM technology is now utilized by brands in over 7,000 stores across the US. CEO Chris Bunka highlights the technology's role in boosting market share and sales for clients like Cannadips and New World CBD. The company plans to introduce five new products powered by DehydraTECH in Q4 2021. Lexaria's tech increases bio-absorption significantly and reduces onset time for cannabinoids and other compounds, with ongoing research and licensing efforts enhancing its market position.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) completed dosing in its second human clinical study, HYPER-H21-2, involving 16 participants assessing the effects of DehydraTECH 2.0-enabled CBD on blood pressure. The study, fully funded by company resources, included continuous monitoring and aims to provide insights into potential blood pressure reduction. Preliminary results are expected in September. Additionally, Lexaria received a second patent in Japan, expanding its intellectual property portfolio to 21 patents granted, enhancing its competitive edge in drug delivery technology.
Lexaria Bioscience Corp. announced it received US$3,817,643 from the exercise of warrants linked to its January 2021 public offering. A total of 580,189 shares were issued at an exercise price of US$6.58 per share. The funds will support its ongoing research programs and general corporate needs, with sufficient capital to sustain operations well into 2022. Lexaria's DehydraTECH technology enhances drug absorption and is licensed to various companies, including a major tobacco firm.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the successful achievement of all objectives in its 2021 antiviral drug program. The company tested five compounds from three antiviral drug classes, achieving up to a three-fold increase in oral drug absorption with its DehydraTECH technology. The results showed significant improvements in bioavailability for drugs like Colchicine and Remdesivir. Next steps include larger efficacy evaluations in infected animals and pursuing collaborations for further product development.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced positive results from its study VIRAL-A20-3, demonstrating that its DehydraTECH technology significantly enhances the delivery of colchicine, a drug with potential anti-inflammatory effects useful in treating SARS-CoV-2/COVID-19 symptoms. The study showed a 91% improvement in peak concentration and a 167% increase in total drug delivery compared to control. The findings suggest potential for improved bioavailability of colchicine, which may allow for lower dosing and enhanced therapeutic effects.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has announced promising results from its antiviral drug study, VIRAL-MC21-1, conducted by the National Research Council of Canada. The study confirms that DehydraTECH technology maintains the chemical stability of five tested antiviral drugs, supporting quicker regulatory approvals via the FDA's 505(b)(2) pathway. Key drugs include remdesivir and colchicine, which are associated with COVID-19 treatment. Lexaria plans to seek collaborations with pharmaceutical partners to enhance the application of DehydraTECH in antiviral therapies.
Lexaria Bioscience Corp. has been granted its first patent in Japan, strengthening its intellectual property portfolio, now totaling 20 patents globally. This patent focuses on stable, ready-to-drink beverage compositions containing lipophilic active agents. Lexaria's innovative DehydraTECH platform enhances the bio-absorption of non-psychoactive cannabinoids and NSAIDs, allowing for healthier ingestion methods. The company aims to expand its patent applications globally, targeting a market of nearly 4 billion people.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has announced plans to voluntarily delist its common shares from the Canadian Securities Exchange (CSE) effective July 7, 2021. Starting July 8, 2021, trading will be consolidated on the Nasdaq Capital Markets, where the majority of trading has already occurred since its Nasdaq debut in January 2021. This decision aims to enhance shareholder liquidity and reduce operational costs, allowing the company to focus its resources on applied research and development programs. Lexaria's shares remain qualified investments for Canadian Registered Savings Plans.
FAQ
What is the current stock price of Lexaria Bioscience Warrant (LEXXW)?
What is Lexaria Bioscience Corp. known for?
In which segments does Lexaria operate?
What are the key benefits of DehydraTECH?
What is the main goal of Lexaria Bioscience Corp.?
How does DehydraTECH impact drug delivery across the blood-brain barrier?
What is the significance of Lexaria's intellectual property portfolio?
Who owns and manufactures GLP-1 drugs like Rybelsus and Ozempic?
What is the focus of Lexaria's ongoing research?
How does Lexaria plan to enhance the delivery of tirzepatide in its latest Study?
What sets Lexaria Bioscience Corp. apart from other innovators in drug delivery platforms?
